399 related articles for article (PubMed ID: 25541953)
1. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.
Peterson J; Gisslen M; Zetterberg H; Fuchs D; Shacklett BL; Hagberg L; Yiannoutsos CT; Spudich SS; Price RW
PLoS One; 2014; 9(12):e116081. PubMed ID: 25541953
[TBL] [Abstract][Full Text] [Related]
2. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.
Gisslén M; Krut J; Andreasson U; Blennow K; Cinque P; Brew BJ; Spudich S; Hagberg L; Rosengren L; Price RW; Zetterberg H
BMC Neurol; 2009 Dec; 9():63. PubMed ID: 20028512
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C.
de Almeida SM; Ribeiro CE; Rotta I; Piovesan M; Tang B; Vaida F; Raboni SM; Letendre S; Potter M; Batistela Fernandes MS; Ellis RJ;
J Neurovirol; 2018 Feb; 24(1):28-40. PubMed ID: 29063514
[TBL] [Abstract][Full Text] [Related]
4. Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression.
Gisslen M; Keating SM; Spudich S; Arechiga V; Stephenson S; Zetterberg H; Di Germanio C; Blennow K; Fuchs D; Hagberg L; Norris PJ; Peterson J; Shacklett BL; Yiannoutsos CT; Price RW
PLoS One; 2021; 16(5):e0250987. PubMed ID: 33983973
[TBL] [Abstract][Full Text] [Related]
5. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.
Gisslén M; Price RW; Andreasson U; Norgren N; Nilsson S; Hagberg L; Fuchs D; Spudich S; Blennow K; Zetterberg H
EBioMedicine; 2016 Jan; 3():135-140. PubMed ID: 26870824
[TBL] [Abstract][Full Text] [Related]
6. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
[TBL] [Abstract][Full Text] [Related]
7. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
8. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
Krut JJ; Zetterberg H; Blennow K; Cinque P; Hagberg L; Price RW; Studahl M; Gisslén M
J Neurol; 2013 Feb; 260(2):620-6. PubMed ID: 23052602
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
13. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
[TBL] [Abstract][Full Text] [Related]
15. Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity.
Anckarsäter R; Anckarsäter H; Bromander S; Blennow K; Wass C; Zetterberg H
J Neural Transm (Vienna); 2014 Jun; 121(6):649-53. PubMed ID: 24420082
[TBL] [Abstract][Full Text] [Related]
16. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
[TBL] [Abstract][Full Text] [Related]
18. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
19. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
20. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease.
Alcolea D; Carmona-Iragui M; Suárez-Calvet M; Sánchez-Saudinós MB; Sala I; Antón-Aguirre S; Blesa R; Clarimón J; Fortea J; Lleó A
J Alzheimers Dis; 2014; 42(1):157-67. PubMed ID: 24820015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
